AiCure LLC

NEW YORK, Jan. 23, 2024 /PRNewswire/ -- AiCure, a prominent AI and advanced data analytics company dedicated to enhancing clinical trials, has recently accomplished a significant funding round. In addition to securing new funds, the company has obtained several new patents, enabling it to advance its technological lead. Furthermore, AiCure is expanding its customer base and attracting new talent. AiCure's innovative software and technology are designed to improve patient engagement and sponsor insights in clinical trials, making it a valuable player in the life sciences industry. With its continued growth and focus on innovation, AiCure is poised to make a lasting impact on the future of clinical research. Continue Reading AiCure announced it has completed a $12M loan refinancing and has also raised an additional $4M+ from its existing supportive investors. In 2023 company also expanded its customer base driven in part by its Clinical Site Services offering which provides ongoing monitoring of site- and patient-level data, targeting operational outcome improvements in adherence and compliance. The new funding and continued expansion of its customer base, place the company in a position of stability as it looks forward to 2024. The infusion of new capital will enable investment in research and development, expansion of operations, and enhance AiCure products and services, ultimately fueling growth and competitiveness in the market. AiCure advances in clinical trials with funding, patents, expanded base, and innovative tech Post this AiCure continues to maintain its technological lead in the industry, receiving seven new US patents in 2023. These patents enhance AiCure's inventive digital biomarker solutions as well as continue to support its core businesses. These additional patents bring AiCure's total patent count in the US to 86, with additional patents issued around the globe. The company has welcomed two new members, Sondra Pepe and Josh Wilson, to its Senior Leadership Team. Sondra Pepe has joined AiCure as the Senior Vice President of Product Management. With nearly 20 years of experience in eClinical SaaS technology, including leading roles in product management at prominent companies such as Medidata, Veeva, Medrio, and ArisGlobal, Sondra brings a wealth of expertise to her new role. She is responsible for leading the product management and testing teams at AiCure, overseeing the product direction, definition, and delivery of the company's award-winning artificial intelligence platform. Josh Wilson has joined AiCure as Senior Vice President of Operations. Mr. Wilson brings with him a wealth of experience, having spent nearly two decades at Syneos Health and INC Research, where he was responsible for building and managing data management and technology implementation teams, as well as driving innovative strategies and strategic vendor engagements. Mr. Wilson oversees the operations teams responsible for delivery of the company's platform and site services. Driven by its Vice President of People Operations, Earnest Offley, AiCure remains at the forefront of women in tech with 42% of its workforce being represented by women. The company's commitment to race and gender diversity is evident in its workforce composition which also lends itself to a diverse Ai data platform. AiCure's responsible Ai self-checks to mitigate racial pigmentation bias. This is a notable achievement in the male-dominated tech industry, reflecting AiCure's efforts to promote inclusivity and gender equality within the workplace and in customer studies. With new funding, new patents, a growing customer base, additional leadership and new strategic initiatives, AiCure is well-positioned to further its mission of enhancing drug development and improving patient care through its innovative AI solutions. For more information, please visit the AiCure website. CONTACT: John Stanton, [email protected] SOURCE AiCure

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- The "Global AI in Clinical Trials Market: Trends and Forecasts 2023-2035" report has been added to ResearchAndMarkets.com's offering. The global AI in clinical trials market is estimated to be worth $ 1.4 billion in 2023 and expected to grow at compounded annual growth rate (CAGR) of 16% during the forecast period. The process of successfully developing a novel therapeutic intervention is both time and cost intensive. In fact, it is estimated that a drug requires around 10 years and over $ 2.5 billion capital investment, before reaching the market. In this process, clinical trials play a crucial role for assessing the drug's efficacy and safety in humans. These trials account for nearly 50% of the time and capital expenditure during drug development. However, sponsors face financial burdens and significant delays in marketing drugs due to unsuccessful clinical trials. Over the past few decades, the success rate of a drug candidate advancing the clinical trials to obtaining marketing approval has remained relatively constant at approximately 10% - 20%. This can be attributed to the factors contributing to clinical stage intervention failure, including inadequate study design, incomplete patient recruitment, improper subject stratification and high rate of clinical trial participant attrition. In order to overcome these challenges and streamline the clinical trial processes, stakeholders in the pharmaceutical industry are exploring innovative solutions and strategies. One such innovative strategy involves integrating AI in drug development, which has the potential to revolutionize traditional methods, particularly in clinical trials. It is worth noting that artificial intelligence in clinical trials can help integrate and analyze large volumes of data, enabling trial sponsors to optimize future research initiatives. Additionally, by addressing issues related to trial design, patient recruitment and retention, site selection, data interpretation, and treatment evaluation, AI has the potential to enhance and refine the entire process of clinical drug development. Moreover, in the first nine months of 2021, more than $20 billion was invested into artificial intelligence companies focused on healthcare, exceeding the prior investment, which was around $15 billion in 2020. Therefore, with the rising interest of investors in this field, we anticipate the AI in clinical trials market to witness healthy growth during the forecast period. Key Market Insights The report features an extensive study of the current market landscape, market size and future opportunities associated with the AI in clinical trials market, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the AI in clinical trials market report are briefly discussed below. Benefits and Growing Demand for Artificial Intelligence Solutions for Patient Recruitment and Clinical Data Analysis AI solutions have emerged as a promising tool in the drug development process. These AI tools help companies improve the accuracy and efficiency of testing, accelerate drug development and optimize clinical trial outcomes. In addition, leveraging AI software in clinical trials helps increasing patient recruitment and retention, reduces trial time and cost, and provides more accurate clinical data analysis, personalized medicine, trial design and real-time patient monitoring. It is worth highlighting that the ability of AI to automate and streamline labor-intensive tasks, improve decision-making processes, and identify patterns and trends in complex datasets has garnered significant attention and interest from stakeholders in the pharmaceutical industry. In May 2023, US based Owkin received letter of support from the European Medicines Agency (EMA) for the use of proprietary deep learning models for oncology clinical trial analysis; the company believes that this can reduce the clinical trial failure rates in randomized clinical trial. Further several artificial intelligence companies have developed AI-powered platforms that optimize patient identification for clinical trials. Additionally, AI algorithms can be trained to analyze large amounts of data in electronic health records to identify eligible participants. Owing to these applications and recognition of the immense potential of AI by researchers and sponsors, the demand for AI clinical trials is likely to continue to grow and transform the landscape of drug development by improving patient outcomes in clinical trials. Current Market Landscape of AI in Clinical Trials: AI Software and Service Providers The AI in clinical trials market landscape features a mix of large, mid-sized and small companies. Currently, around 130 players have the required expertise to offer various software and services to streamline clinical studies. Notably, at present, around 80% of these AI in clinical trials software and service providers are focusing on leveraging machine learning and deep learning algorithms, as they minimize data-based errors by accessing various data points simultaneously. Recent developments in this field indicate that the artificial intelligence companies in clinical trials are upgrading their capabilities to accommodate the current and anticipated demand for these software and services. Partnership and Collaboration Trends in the AI in Clinical Trials Market In recent years, several artificial intelligence companies have inked partnerships related to AI in clinical trials domain with other industry / non-industry players. It is worth highlighting that, since 2018, a significant number of strategic partnerships have been inked in the AI in clinical trials industry. It is worth highlighting that product / technology utilization and integration agreements are the most common types of partnerships inked by stakeholders in the AI clinical trials field. Owing to several advantages of artificial intelligence in clinical trials, stakeholders are acquiring other industry players offering AI solutions / AI software for different clinical trial applications in order to expand their capabilities and build a comprehensive product / service portfolio. In February 2023, ZS acquired Trials.ai, an intelligent study design company, to enhance its end-to-end solutions to reimagine study design for its clients. In addition, several big pharma companies, such as Bristol Myers Squibb, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Pfizer and Roche, have also taken partnership initiatives related to AI in clinical trials, indicating the promise and benefits that AI technology holds in clinical trials. Key Trends in the AI in Clinical Trials Market In the past six years, around 600 completed / ongoing clinical trials utilized AI tools and technologies for evaluating drugs / therapies for different therapeutic areas, indicating the substantial efforts made by researchers engaged in this domain. Further, most of the clinical studies were designed for the purpose of diagnostics and treatment. It is worth noting that the University of California, the National Institute of Allergy and Infectious Diseases, and Mayo Clinic are among the most active sponsors of completed / ongoing clinical trials involving AI solutions. Rise in Investment in AI in Clinical Trials Market The heightened interest in the AI in clinical trials market can be validated by the fact that, in the last five years, close to $2.5 billion has been invested in companies engaged in providing AI software and services for clinical trials by several investors based across the globe. The majority of the funds have been raised through venture rounds, followed by seed financing rounds. In addition, several big pharma players, such as Bristol Myers Squibb, Merck, Novartis, Pfizer and Sanofi have also invested in AI software and service providers for clinical trials. In June 2021, Antidote Technologies raised $23 million to expand its digital patient engagement programs and clinical trial recruitment services. AI in Clinical Trials Market Size Driven by the rising demand for artificial intelligence in clinical trials, lucrative opportunities are expected to emerge for players offering AI technology for clinical studies. The global market for AI in clinical trials is anticipated to grow at a significant pace, with a CAGR of 16% during the forecast period. Among the therapeutic areas for which AI tools are leveraged in clinical trials, oncological disorders are most likely to adopt these AI solutions for streamlining processes, such as patient recruitment and retention, trial design, site selection, clinical data analysis, patient monitoring and personalized treatment. In terms of end-users, biotechnology and pharmaceutical companies are likely to hold the majority share (75%) of the AI in clinical trials market. Key Artificial Intelligence Companies Supporting Clinical Trials Examples of the key companies engaged in the AI in clinical trials domain (the complete list of players is available in the full report) include (in alphabetic order) Acclinate, AiCure, Aidar Health, Aitia, A.I. VALI, Ancora.ai, Antidote Technologies, Beacon Biosignals, BUDDI.AI, ConcertAI, Curify, Deep 6 AI, ICON, Innoplexus, Massive Bio, Median Technologies, Novadiscovery, Owkin, PHASTAR, SiteRx and Viz.ai. This market report also includes an easily searchable excel database of all the AI software / AI solutions and service providers for clinical trials worldwide. Scope of the Report The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments. The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. The opinions and insights presented in the report were influenced by discussions held with stakeholders in this industry. The report also features detailed transcripts of interviews held with various industry stakeholders: Danielle Ralic (Co-Founder, Chief Executive Officer and Chief Technology Officer, Ancora.ai) Wout Brusselaers (Founder and Chief Executive Officer, Deep 6 AI) Dimitrios Skaltsas (Co-Founder and Executive Director, Intelligencia) R. A. Bavasso (Founder and Chief Executive Officer, nQ Medical) Grazia Mohren (Head of Marketing), Michael Shipton (Chief Commercial Officer), Darcy Forman (Chief Delivery Officer), Troy Bryenton (Chief Technology Officer, Science 37) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Key Topics Covered 1. PREFACE 1.1. Introduction 1.2. Key Market Insights 1.3. Scope of the Report 1.4. Research Methodology 1.5. Frequently Asked Questions 1.6. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Overview of Artificial Intelligence (AI) 3.3. Subfields of AI 3.4. Applications of AI in Healthcare 3.4.1. Drug Discovery 3.4.2. Drug Manufacturing 3.4.3. Marketing 3.4.4. Diagnosis and Treatment 3.4.5. Clinical Trials 3.5. Applications of AI in Clinical Trials 3.6. Challenges Associated with the Adoption of AI 3.7. Future Perspective 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. AI in Clinical Trials: AI Software and Service Providers Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Location of Headquarters 4.2.4. Analysis by Company Size and Location of Headquarters (Region) 4.2.5. Analysis by Key Offering(s) 4.2.6. Analysis by Business Model(s) 4.2.7. Analysis by Deployment Option(s) 4.2.8. Analysis by Type of AI Technology 4.2.9. Analysis by Application Area(s) 4.2.10. Analysis by Potential End-user(s) 5. COMPANY PROFILES 5.1. Chapter Overview 5.2. AiCure 5.3. Antidote Technologies 5.4. Deep 6 AI 5.5. Innoplexus 5.6. IQVIA 5.7. Median Technologies 5.8. Medidata 5.9. Mendel.ai 5.10. Phesi 5.11. Saama Technologies 5.12. Signant Health 5.13. Trials.ai 6. CLINICAL TRIAL ANALYSIS 6.1. Chapter Overview 6.2. Scope and Methodology 6.3. AI in Clinical Trials 6.3.1. Analysis by Trial Registration Year 6.3.2. Analysis by Number of Patients Enrolled 6.3.3. Analysis by Trial Phase 6.3.4. Analysis by Trial Status 6.3.5. Analysis by Trial Registration Year and Status 6.3.6. Analysis by Type of Sponsor 6.3.7. Analysis by Patient Gender 6.3.8. Analysis by Patient Age 6.3.9. Word Cloud Analysis: Emerging Focus Areas 6.3.10. Analysis by Target Therapeutic Area 6.3.11. Analysis by Study Design 6.3.12. Most Active Players: Analysis by Number of Clinical Trials 6.3.13. Analysis of Clinical Trials by Geography 6.3.14. Analysis of Clinical Trials by Geography and Trial Status 6.3.15. Analysis of Patients Enrolled by Geography and Trial Registration Year 6.3.16. Analysis of Patients Enrolled by Geography and Trial Status 7. PARTNERSHIPS AND COLLABORATIONS 7.1. Chapter Overview 7.2. Partnership Models 7.3. AI in Clinical Trials: List of Partnerships and Collaborations 7.3.1. Analysis by Year of Partnership 7.3.2. Analysis by Type of Partnership 7.3.3. Analysis by Year and Type of Partnership 7.3.4. Analysis by Application Area 7.3.5. Analysis by Target Therapeutic Area 7.3.6. Analysis by Type of Partner 7.3.7. Most Active Players: Analysis by Number of Partnerships 7.3.8. Analysis by Geography 8. FUNDING AND INVESTMENT ANALYSIS 8.1. Chapter Overview 8.2. Types of Funding 8.3. AI in Clinical Trials: List of Funding and Investments 8.3.1. Analysis by Year of Funding 8.3.2. Analysis by Amount Invested 8.3.3. Analysis by Type of Funding 8.3.4. Analysis by Type of Funding and Amount Invested 8.3.5. Most Active Players: Analysis by Amount Raised and Number of Funding Instances 8.3.6. Leading Investors: Analysis by Number of Funding Instances 8.3.7. Analysis of Amount Invested by Geography 8.3.8. Analysis of Number of Funding Instances by Geography 8.4. Concluding Remarks 9. BIG PHARMA INITIATIVES 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Analysis by Year of Initiative 9.4. Analysis by Type of Initiative 9.5. Analysis by Application Area of AI 9.6. Analysis by Target Therapeutic Area 9.7. Benchmarking Analysis: Big Pharma Players 10. AI IN CLINICAL TRIALS: USE CASES 10.1. Chapter Overview 10.2. Use Case 1: Collaboration between Roche and AiCure 10.3. Use Case 2: Collaboration between Takeda and AiCure 10.4. Use Case 3: Collaboration between Teva Pharmaceuticals and Intel 10.5. Use Case 4: Collaboration between Unnamed Pharmaceutical Company and Antidote 10.6. Use Case 5: Collaboration between Unnamed Pharmaceutical Company and Cognizant 10.7. Use Case 6: Collaboration between Cedars-Sinai Medical Center and Deep 6 AI 10.8. Use Case 7: Collaboration between GlaxoSmithKline (GSK) and PathAI 10.9. Use Case 8: Collaboration between Bristol Myers Squibb (BMS) and Concert AI 11. VALUE CREATION FRAMEWORK: A STRATEGIC GUIDE TO ADDRESS UNMET NEEDS IN CLINICAL TRIALS 11.1. Chapter Overview 11.2. Unmet Needs in Clinical Trials 11.3. Key Assumptions and Methodology 11.4. Key Tools / Technologies 11.4.1. Blockchain 11.4.2. Big Data Analytics 11.4.3. Real-world Evidence 11.4.4. Digital Twins 11.4.5. Cloud Computing 11.4.6. Internet of Things (IoT) 11.5. Trends in Research Activity 11.6. Trends in Intellectual Capital 11.7. Extent of Innovation versus Associated Risks 11.8. Results and Discussion 11.9. Summary 12. COST SAVING ANALYSIS 12.1. Chapter Overview 12.2. Key Assumptions and Methodology 12.3. Overall Cost Saving Potential of AI in Clinical Trials, 2023-2035 12.3.1. Cost Saving Potential in Phase I Clinical Trials, 2023-2035 12.3.2. Cost Saving Potential in Phase II Clinical Trials, 2023-2035 12.3.3. Cost Saving Potential in Phase III Clinical Trials, 2023-2035 12.3.4. Cost Saving Potential in Patient Recruitment, 2023-2035 12.3.5. Cost Saving Potential in Patient Retention, 2023-2035 12.3.6. Cost Saving Potential in Staffing and Administration, 2023-2035 12.3.7. Cost Saving Potential in Site Monitoring, 2023-2035 12.3.8. Cost Saving Potential in Source Data Verification, 2023-2035 12.3.9. Cost Saving Potential in Other Procedures, 2023-2035 13. MARKET SIZING AND OPPORTUNITY ANALYSIS 13.1. Chapter Overview 13.2. Forecast Methodology and Key Assumptions 13.3. Global AI in Clinical Trials Market, 2023-2035 13.3.1. AI in Clinical Trials Market: Distribution by Trial Phase, 2023 and 2035 13.3.2. AI in Clinical Trials Market: Distribution by Target Therapeutic Area, 2023 and 2035 13.3.3. AI in Clinical Trials Market: Distribution by End-user, 2023 and 2035 13.3.4. AI in Clinical Trials Market: Distribution by Key Geographical Regions, 2023 and 2035 14. CONCLUSION 15. EXECUTIVE INSIGHTS 16. APPENDIX I: TABULATED DATA 17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned AbbVie Accelmed Accenture Acclinate Actelion Pharmaceuticals Adara Ventures AG Mednet Agent Health A.I. VALI AiCure Aidar Health AITIA AKESOgen AKRN Scientific Consulting (acquired by NAMSAN) Alexandria Venture Investments Alira Health AliveCor AllianceBernstein Alliance for Clinical Trials in Oncology Allucent Alpha MD ALS Association Alter Venture Partners Amadeus Capital Partners Amber Specialty Pharmacy American Society of Clinical Oncology (ASCO) Amgen Amgen Ventures Amplify Ancora.ai Anthem Anthemis Exponential Ventures Antidote Technologies Aperio APEX Digital Health APEX Ventures Arondor Artificial Intelligence in Medicine (AIM) (a subsidiary of Inspirata) ArtiQ Arvinas Asahi Kasei Ascension Ventures Aspen Insights Assistance Publique Hopitaux de Paris AstraZeneca ATAI Life Sciences AV8 Ventures Avalanche Venture Capital Avident Health Avira Digital Aviva Ventures Avon Baird Capital Baron Davis Enterprises Beacon Biosignals BEPATIENT Beyond Celiac Big Pi Ventures Bioforum Biofourmis Bioinfogate (acquired by Clarivate) Biomatics Capital Biomedical Advanced Research and Development Authority (BARDA) Blue Heron Capital Boehringer Ingelheim Boehringer Ingelheim Venture Fund (BIVF) Bold Capital Partners Bolton NHS Foundation Trust BootstrapLabs Boreal Ventures Bpifrance Brainomix Brainpan Innvovations Bridge Biotherapeutics Bristol Myers Squibb (BMS) Brite Health Bronze Valley BUDDI.AI BullFrog AI Cambridge Cognition Canary Speech Carebox Carenity (acquired by EvidentIQ) Carle Health Carlyle Casdin Capital Cathay Innovation Cavendish Impact Foundation (CIF) Cedar Health Research Celgene CellCarta Central Ohio Primary Care Physicians (COPC) The Centre for Aging + Brain Health Innovation (CABHI ) Cerba Research Chainlink Charterhouse Capital Partners Chartline Capital Partners ChemAxon Children's Oncology Group (COG) Chimera Partners Cigna Ventures CIMS Global Citeline ( a subsidiary of Norstella) Clario Clarivate ClearPoint Investment Partners Clinerion Clinevo Technologies clinicalAI CliniOps Clinithink ClinScape ClinTex CMIC Group Cognizant Community Health Network ConcertAI Constant Companion Creadev Crestle.ai (acquired by Doc.ai) Crista Galli Ventures Cumulus Neuroscience Curenetics Curify.ai CVS Health Dassault Systemes DataON Datavant DCM Ventures DCVC Bio Debiopharm Decibel Therapeutics Declaration Partners Deep 6 AI Deep Lens (acquired by Paradigm) DeepTrial Defense Health Agency Dementia Discovery Fund (DDF) Department of Veteran Affairs Deutsche Investitions und Entwicklungsgesellschaft (DEG) DiA Imaging Analysis doc.ai (acquired by Sharecare) Dong-A Socio Holdings EBSCO Information Services Echo Health Ventures EDBI Edison Partners Eight Roads Ventures eimageglobal EIT Health Elliott Investment Management Entrepreneur First Epilepsy Study Consortium Ergomed Erlanger Health System ERYTECH Espresso Capital Eugene M. Lang Foundation European Commission European Investment Bank European Regional Development Fund (ERDF) Excelra Experimental Cancer Medicine Centre (ECMC) Experimind Faber fathom it group FinLab EOS VC Fund First Analysis Corporation First Trust Capital Partners Florida Cancer Affiliates Folklore Ventures Fosun RZ Capital GE Healthcare Genentech General Atlantic General Catalyst Genoa Ventures Genomenon Genpro Research GlaxoSmithKline (GSK) Global Alzheimer's Platform Foundation Gloucestershire Cancer Alliance (SWAG) Google GV (formerly Google Ventures) Greater Gift Grey Sky Venture Partners Grove Ventures GSR Ventures Guy's and St Thomas' NHS Foundation Trust H1 H2O.ai Halo Health Hambro Perks Healint Healthix HealthMatch HealthVerity Hematology-Oncology Associates of Central New York (HOA) Jiangsu Hengrui Pharmaceuticals Herefordshire and Worcestershire Health and Care NHS Trust Heritage Medical Group Highline Sciences HCLTech Horizon Therapeutics Human API IBM iClusion ICON IKJ Capital iLoF IMA Group IMNA Solutions ImpactAssets Inato Indegene iNDX.Ai Inflection Biosciences Innoplexus Innovaderm Innovatrix Capital Insight Partners Insilico Medicine Inspirata Inspire Intel Intel Capital (a subsidiary of Intel) Intelligencia.ai Intermountain Ventures Investissement Quebec Iowa First Capital Fund Iowa Innovation Acceleration Fund IQ Capital IQVIA IXICO Janssen Pharmaceuticals Jianke Johns Hopkins University Johnson & Johnson Karyopharm Therapeutics Keosys Khosla Ventures King's Health Partners Kinship Kleiner Perkins Kognitic Labcorp Lambda Therapeutic Research LaunchCapital Launch Therapeutics LBO France Leal Health Legit.Health LEO Pharma Leukemia & Lymphoma Society Lieber Institute for Brain Development Life Image (acquired by Intelerad Medical SystemsT ) LifeArc Lightship Linguamatics (a subsidiary of IQVIA) Liquid 2 Ventures LMK Clinical Research Consulting Lokavant (a subsidiary of Roivant Sciences) LSU Health New Orleans Lunar Ventures M12 (formerly known as Microsoft Ventures) Massachusetts General Hospital Massive Bio MassMutual Ventures Matrix Capital Management Matrix Partners Maverick Ventures Maxer Consulting Mayfield Fund Mayo Clinic Mayo Clinic Ventures (a subsidiary of Mayo Clinic) McKesson Ventures (a subsidiary of McKesson) Medable Median Technologies Medica Medical Research Network (MRN) Medidata Solutions mediri Medpace MEDSOFT Medtronic Memorial Sloan Kettering Cancer Center (MSK) Mendel.ai Menlo Ventures Merck Merck Global Health Innovation Fund (Merck GHI) (a subsidiary of Merck) Microsoft Millennium Technology Value Partners Mitsui Moderna MSD Global Health Innovation Fund (MGHIF) MTIP Mubadala Capital Nanox National Cancer Institute (NCI) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Mental Health (NIMH) National Minority Health Association (NMHA) NEC NEC OncoImmunity (a subsidiary of NEC) NeoGenomics NetraMark NeuroEndocrine Cancer Australia New Enterprise Associates New Leaf Venture Partners Nex Cubed Next Level Ventures nference NJF Capital Nor-Tech North American Science Associates (NAMSA) Northpond Ventures Nova Discovery Novartis Novoic Novotech nQ Medical Nucleai NuvoAir Oak HC/FT Obvious Ventures Ocala Oncology Octopus Ventures Olive Tree OMRON Healthcare OncoBay Clinical OncoSec Medical One Nucleus OneStudyTeam Openspace Ventures Opyl Oracle Otium Venture ?URA Health Overline Venture Capital Owkin Oxford Finance University of Oxford Innovation Fund (UOIF) P1vital P360 P3Life Paige AI Palisades Growth Capital Pancare Foundation Pangaea Data Paradigm Parexel Parkwalk Advisors Partech Passage AI Patchai (acquired by Alira Health) PathAI Patient iP PatientPoint PatienTrials Patiro Pear Therapeutics Pepgra Perceiv AI Perceptive Advisors Perthera.ai Pfizer Pfizer Ventures (a subsidiary of Pfizer) Pharmamodelling Phastar phaware Phesi physIQ Plug and Play Ventures Point72 Ventures Population Health Partners PPC (merged with Novotech) PRA Health Sciences Precipio Prime Capital Pritzker Group ProofPilot Propeller Health Protocols.io PWNHealth Qmetrics Technologies Qualcomm Ventures Quality Cancer Care Alliance Network (QCCA) Quibim Quiet Capital Qure.ai Qwince Radical Ventures RadMD (acquired by Medica Group) Raylytic re.Mind Capital RealTime Software Solutions Red Abbey Labs Reify Health Remarque Systems Renmin Hospital of Wuhan University Rev1 Ventures Revo Capital Revolution Growth Risklick Rittenhouse Ventures Roche Roivant Sciences Royal Philips Rural Vitality Fund Rymedi Saama Technologies San Raffaele Hospital Sanofi Sanofi Ventures (a subsidiary of Sanofi) Scale Ventures Science37 Scipher Medicine Self-Care Catalysts Semicrol sensedat Sensyne Health Sequoia India Serena and Fly Ventures ServiceNow Servier SGInnovate Shandong University Sierra Ventures Sigmasoft Signant Health Silicon Valley Bank (SVB) SimBioSys Singtel Innov8 SiteGround Capital SiteRx Sixth Street Small Business Innovation Research (SBIR) Smedvig Capital SoftBank Vision Fund Somerset Sopris Capital SOSV Sourcia Southern Oncology Specialists Sozo Ventures SpringRock Ventures Square Peg Square Peg Capital Stanford Angels Stratus SubjectWell Sway Ventures SyMetric Symphony Clinical Research (acquired by ICON) SymphonyAI Syneos Health Synetro Synexus System Applications and Products in Data Processing (SAP) T. Rowe Price Taliaz Talkdesk Tamarind Hill Fund Teal Ventures Tech Transfer UPV TEDCO's Seed Fund Tempus Tencent Holdings Tenthpin TeraRecon TFS Services The Angels' Forum ThoughtSphere THREAD Tiger Global Management Timberline Holding TissueTech Translational Drug Development (TD2) TransPerfect Life Sciences Trialbee Trials.ai (acquired by ZS Associates) TrialSense Tribeca Venture Partners TriNetX TT Capital Partners TTi Health Research & Economics U.S. Food and Drug Administration (FDA) U.S. Veteran's Affairs UCB Biopharma UK Future Fund Underscore Venture Capital UnityPoint Health Ventures University of California University of Pennsylvania University of Pittsburgh Unlearn.AI Vastrax VeriSIM VersaTrial Vertex Ventures Veterans Prostate Cancer Awareness (VPCa) VIDA Viroclinics-DDL (acquired by Cerba HealthCare) VirTrial Vivoryon Therapeutics Viz.ai WallachBeth Capital WCG Clinical Wefight Wiley Winterlight Labs Wittington Ventures Worldwide Clinical Trials WP Global Partners XpertPatient Zola Global Investors ZS Associates For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Growth Opportunities and Innovative Use Cases for AI in Clinical Trials" report has been added to ResearchAndMarkets.com's offering. As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs. The rapid adoption of AI/ML algorithms and platforms to structure and utilize electronic health records (EHRs) allows the industry to tap into a vast, rich, and highly relevant data source that holds tremendous potential in improving the global clinical trial landscape. Incorporating integrated AI-driven solutions in clinical trial design and patient retention will ease the go-to-market strategy for various CROs and pharma players as they will reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, as well as engagement through interactive platforms thus ensuring higher retention. Additionally, these platforms are highly beneficial in the selection of appropriate investigators and trial sites. Randomized control trials (RCTs) are another possible application for sponsors to leverage AI in analyzing vast site-level datasets for greater insight into trial design and implementation. Leading CROs such as Syneos Health or IQVIA, as well as several pharmaceutical companies such as BMS, have successfully deployed AI-based platforms to support site selection and patient recruitment. Companies (including AstraZeneca and Novartis among others) are also applying AI in clinical trials to enable the optimization of different stages with the intent of reducing the overall trial timelines. AI technologies bring fundamental innovations for transforming clinical trials, such as collecting and analyzing real-world data, seamlessly combining phases I and II of clinical trials, and developing novel patient-centered endpoints. AI can be leveraged to create standardized, structured, and digital data elements from a range of inputs, and as AI-enabled study design helps optimize and accelerate the creation of patient-centric designs, it significantly reduces patient burden, increases the likelihood of success, decreases the number of amendments, and improves the overall efficiency of trials. Together, big technology providers and pharmaceutical start-ups are setting the course for more effective clinical trials in the future. Key Issues Addressed What are the key trends impacting the clinical trial industry in terms of technology implementation? What are the various application areas for AI in terms of execution of clinical trials? Who are some of the key industry stakeholders building cutting-edge AI enabled platforms? What are the industry drivers and barriers impacting the AI enabled clinical trial industry? What are the key strategies global stakeholders are taking to better serve customers while ensuring growth? What are the key growth opportunities going forward and call to action for CROs, sponsors and technology participants in the ecosystem? Key Topics Covered: 1. Strategic Imperatives 2. Growth Opportunity Analysis Scope of Analysis Definitions Segmentation The Top 3 Clinical Trial Challenges The AI Value Proposition in Clinical Trials Why AI Is Critical for Trial Success The Patient Journey Through AI-enabled Clinical Trials Growth Drivers Growth Restraints Regulatory Scenario-AI Use in Clinical Trials Vendor Ecosystem AI in Clinical Trials-Companies-to-Action (C2A) Targets AI in Clinical Trials-Adoption Timeline and Impact 3. Use Case-Clinical Trial Design AI Applications in Clinical Trial Design Vendor Spotlight-Owkin Industry Use Case and Analyst Perspective Vendor Spotlight-ConcertAI Industry Use Case and Analyst Perspective Other AI Vendors in Clinical Trial Design 4. Use Case-Patient Enrichment, Recruitment, and Enrollment AI Application in Patient Enrichment, Recruitment, and Enrollment Vendor Spotlight-Unlearn Industry Use Case and Analyst Perspective Vendor Spotlight-TrialWire Analyst Perspective Other AI Vendors for Patient Enrichment, Recruitment, and Enrollment 5. Use Case-Patient Monitoring, Medical Adherence, and Retention AI Application in Patient Monitoring, Adherence, and Retention Vendor Spotlight-AiCure Industry Use Case and Analyst Perspective Vendor Spotlight-AWS Industry Use Case and Analyst Perspective Other AI Vendors for Patient Monitoring, Adherence, and Retention 6. Use Case-Investigator and Site Selection AI Applications in Investigator and Site Selection Vendor Spotlight-Medidata AcornAI Industry Use Case and Analyst Perspective Vendor Spotlight-Deep 6 AI Industry Use Case and Analyst Perspective Other AI Vendors for Investigator and Site Selection 7. Other Companies to Watch 8. Growth Opportunity Universe Growth Opportunity 1-Remote Recruitment to Expand Patient Diversity for Cancer Trials Growth Opportunity 2-Patient-centric Clinical Trial Design for Better Retention and Monitoring Growth Opportunity 3-AI-integrated Cloud-based SaaS Delivery Models List of Exhibits A selection of companies mentioned in this report includes AiCure AWS ConcertAI Deep 6 AI Medidata AcornAI Owkin TrialWire Unlearn For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets